<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892112</url>
  </required_header>
  <id_info>
    <org_study_id>MD2009.01</org_study_id>
    <nct_id>NCT00892112</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy</brief_title>
  <official_title>Immunoglobulin Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Parvovirus B19 Persistence - a Prospective, Double-blind, Randomized, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanquin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized double-blind placebo-controlled trail to investigate the effect of
      high doses of IVIg on cardiac functional capacity and virus presence in a subgroup of
      patients with chronic symptomatic ICM and a high PVB19 load in the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Parvovirus B19 (PVB19) persistence in the heart has been associated with
      progressive cardiac dysfunction and evolution to idiopathic cardiomyopathy.

      Objective: A controlled trial to investigate whether high dose of intravenous immunoglobulin
      (IVIg) in addition to conventional heart failure therapy in patients with idiopathic
      cardiomyopathy and PVB19 persistence in the heart achieves improvement of cardiac function in
      conjunction with virus elimination.

      Study design: All patients will undergo routine diagnostic work-up (including physical
      examination, coronary angiogram, transthoracic echocardiogram, blood studies and
      endomyocardial biopsies (EMB)), treatment and follow-up for their heart failure. Patients
      will be randomized to either receive IVIg or placebo on top of their standard heart failure
      regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main study parameter is the change in cardiac ejection fraction presence of the heart from baseline to endpoint.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives include changes in presence of cardiotrophic viruses, inflammation , fibrosis, cardiac functional capacity, patient quality of life, other echocardiographic parameters.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myocardial Diseases</condition>
  <condition>Parvovirus B19, Human</condition>
  <arm_group>
    <arm_group_label>intravenous immunoglobulins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV, 40 ml/kg over 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>plasma volume expander Albuman</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV, 40 ml/kg over 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Immunoglobulins</intervention_name>
    <description>2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days</description>
    <arm_group_label>intravenous immunoglobulins</arm_group_label>
    <other_name>Nanogam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>plasma volume expander</intervention_name>
    <description>10 ml/kg BW will be administrated on four consecutive days.</description>
    <arm_group_label>plasma volume expander Albuman</arm_group_label>
    <other_name>G.P.O. (&quot;Gepasteuriseerde Plasma-eiwit Oplossing&quot;)</other_name>
    <other_name>Albuman 40 g/l</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic cardiomyopathy (LVEF &lt;45%) &gt;6months

          -  Optimal conventional heart failure medication &gt;3 months.

          -  PVB19 viral load &gt;200 copies/mcg DNA in endomyocardial biopsies (EMBs).

          -  Signed informed consent

          -  Aged between 18 and 75 years

        Exclusion Criteria:

          -  Other causes for heart failure

          -  Significant coronary artery disease (lesions &gt;70 % stenosis)

          -  Significant valvular disease

          -  Untreated hypertension (blood pressure &gt;140mmHg)

          -  Substance abuse

          -  Chemotherapy induced

          -  Significant titer of other cardiotrophic viruses (EV, ADV, HHV6, EBV)

          -  Pregnancy or lactation

          -  Systemic diseases such as sarcoidosis, giant cell myocarditis, hemochromatosis, or
             systemic autoimmune diseases.

          -  Treatment with any other investigational drug within 7 days before study entry or
             previous enrolment in this study

          -  Known with allergic reactions against human plasma or plasma products

          -  Having an ongoing progressive terminal disease, including HIV infection

          -  Having renal insufficiency (plasma creatinin &gt;115µmol/L or creatinin clearance &lt;20
             ml/min)

          -  Having an ongoing active disease causing general symptoms e.g. chronic active
             hepatitis, persistent enterovirus infection with ongoing systemic complaints

          -  Having detectable anti-IgA antibodies

          -  Active SLE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Heymans, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZM, Maastricht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>I Kleine Budde, PhD</last_name>
    <email>i.kleinebudde@sanquin.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZM</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Heymans, PhD, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>M Hazebroek, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>R Dennert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>S Heymans, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Casper GM Eurlings, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Hazebroek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jort Merken, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunoglobulins, Intravenous</keyword>
  <keyword>Cardiomyopathies</keyword>
  <keyword>Parvo B19, Human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Parvoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Plasma Substitutes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

